Please join the Melanoma Research Alliance and the Society for Immunotherapy in Cancer for a Congressional briefing to hear about promising new areas of research involving immunotherapy and melanoma.
Melanoma is one of the top five cancers by incidence in the U.S. (National Cancer Institute SEER), and its rates are only rising. Although we’ve seen advances in diagnosis and treatment, the rising incidence rate and static death rate from melanoma over 30 years cries out for attention. According to SEER, in 2014 alone more than 76,000 Americans will be diagnosed with melanoma – one every eight minutes – and more than 9,700 Americans are expected to die of melanoma – one every hour. Almost twice as many men in the US die from melanoma than women. Six new drugs have been approved by the U.S. FDA since 2011 building on knowledge of the human genome and decades of cancer research investments.
This luncheon briefing will highlight the exciting new classes of therapies in the pipeline aimed at the treatment of cancers such as melanoma. Immunotherapy is just one approach that is showing promise in this evolving research landscape.
Welcome Remarks: Wendy K.D. Selig, President and CEO of the Melanoma Research Alliance
Keynote: James L. Gulley, M.D., Ph.D., Chief, Genitourinary Malignancies Branch, Head, Immunotherapy Section, Center for Cancer Research, National Cancer Institute
– Dr. Howard Kaufman, President, Society for Immunotherapy of Cancer, Associate Director for Clinical Sciences, Rutgers Cancer Institute of New Jersey
– Dr. Jennifer Gansert, Amgen
– T.J. Sharpe, Stage 4 melanoma patient and blogger, Ft. Lauderdale, FL
Please RSVP to Katie Schubert at email@example.com or (202) 484-1100 x111
This is a widely attended event.
Briefing made possible by an educational grant from Amgen